LONDON--(BUSINESS WIRE)--The global Lennox-Gastaut syndrome (LGS) treatment market is expected to post a CAGR of close to 5% during the period 2019-2023, according to the latest market research report ...
SAN DIEGO, April 6, 2026 /PRNewswire/ -- The Lennox-Gastaut Syndrome (LGS) Foundation and community are mobilizing Walks for LGS Research around the country this month. This national event unites ...
The Lennox-Gastaut Syndrome (LGS) Market focuses on treatments and therapies for managing this severe and rare form of epilepsy, typically starting in childhood. LGS is characterized by multiple types ...
FINTEPLA® (fenfluramine) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients two years of ...
November 1, International Lennox-Gastaut Syndrome Awareness Day, is beig observed for the first time in Romania by the Association of Patients with Epilepsy (ASPERO), which will carry out an awareness ...
SKYLINE Study in Dravet Syndrome Narrowly Missed its Primary Endpoint of Reduction in Convulsive Seizure Frequency and Showed Clinically Meaningful and Nominally Significant Effects in Multiple Key ...
The Lennox-Gastaut Syndrome (LGS) Foundation and community are mobilizing Walks for LGS Research around the country this month. This national event unites families, researchers, clinicians, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results